Clinical trials: Donor
Hematologic Malignancy, AML
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
The purpose of this trial is to determine if selectively removing only a small subset of T cells, called CD8+ T cells, is safe and if it can reduce the risk of graft versus host disease (GVHD) without losing the anti-cancer…
- Conditions
- Hematologic Malignancy, AML, ALL, CML
- Trial name
- NCT00333190
- Testing
- CD+8 T cell depletion
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Sickle Cell Anemia, Beta Thalassemia
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia
Background: Sickle cell disease (SCD) is an inherited disorder of the blood. It can damage a person s organs and cause serious illness and death. A blood stem cell transplant is the only potential cure for SCD.
- Trial name
- NCT05357482
- Testing
- TBI, Hydroxyurea, briquilimab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Health Related Quality of Life
Health Related Quality of Life Assessment In Egyptian Recipients After Living Donor Liver Transplantation
Health Related Quality of Life Assessment In Egyptian Recipients After Living Donor Liver Transplantation
- Trial name
- NCT01784497
- Where
- Egypt
- Volunteers
- 35 people
- Sponsor
- Ain Shams University
Type 1 Diabetes, Insulin-requiring Type 2 Diabetes Mellitus
Use of Closed Loop Insulin Delivery for Glucose Control in Patients With Insulin Dependent Diabetes Mellitus After Kidney Transplantation
This study will be a prospective, single center, randomized controlled parallel group open-label trial. Participants with insulin requiring diabetes mellitus who have been offered an organ for living or deceased donor kidney…
- Conditions
- Type 1 Diabetes, Insulin-requiring Type 2 Diabetes Mellitus, End Stage Renal Disease (ESRD)
- Trial name
- NCT04189510
- Testing
- Artificial Pancreas, Multiple Daily Injections
- Sponsor
- University of Virginia
Acute Myeloid Leukemia, Myelodysplastic Syndrome
VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
Patients included in the study with high risk acute myeloid leukemia or myelodysplastic syndrome as defined will receive an allogeneic transplantation conditioned by either myeloablative or reduced regimen.
- Trial name
- VIDAZA-DLI (NCT01541280)
- Testing
- Azacitidine, DLI
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Nantes University Hospital
Delayed Function of Renal Transplant
Effects of the Use of "de Novo" Everolimus in Renal Tranplant Population
This is an open, randomized, single-center study. The selected patients will be first divided into two major groups according to the type of organ to be transplanted: standard criteria donor (SCD) or extended criteria (ECD)…
- Trial name
- NCT01663805
- Testing
- Everolimus
- Where
- 3 sites in Brazil
- Volunteers
- 80 people
- Sponsor
- MARIO ABBUD FILHO
Leukemia, Myelodysplastic Syndromes
Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes
RATIONALE: Photopheresis treats the patient's blood with drugs and ultraviolet light outside the body and kills the white blood cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00045305
- Testing
- Cyclosporine, Methotrexate, Photopheresis
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Eastern Cooperative Oncology Group
Waning Donor Chimerism, Waning Immune Function
CD34+ Stem Cell Infusion to Augment Graft Function
The purpose of this study is to determine if infusing additional special donor cells will help to improve graft or immune function in previously transplanted children with immune deficiencies and bone marrow failures.
- Conditions
- Waning Donor Chimerism, Waning Immune Function, Primary Immunodeficiency Disease(s), Bone Marrow Failure
- Trial name
- NCT01856582
- Testing
- CD34+
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Diabetes Mellitus, Heart Failure
Diabetes and Lipid Accumulationand Heart Transplant
Idiopathic dilated cardiomyopathy (IDC) is defined by the presence of left ventricular systolic dysfunction in the absence of an abnormal loading condition or significant coronary artery disease.
- Trial name
- DCM-AHEAD (NCT03546062)
- Testing
- patients treated by HTx
- Where
- 2 sites in Italy
- Volunteers
- 177 people
- Sponsor
- University of Campania Luigi Vanvitelli
Hematologic Neoplasms
National Marrow Donor Program Long-Term Donor Follow-Up
This is an observational study of unstimulated bone marrow (BM) and filgrastim-mobilized peripheral blood stem cell (PBSC) donors.
- Trial name
- LTDFU (NCT01362179)
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 21,974 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Delayed Graft Function
TxAccess and Dd-cfDNA for Improved Care of Patients With Delayed Graft Function
This is a prospective multicenter nonrandomized pragmatic hybrid effectiveness-implementation study to test the effectiveness of TxAccess in improving time to renal recovery and immunologic outcomes in patients with delayed graft…
- Trial name
- NCT07825688
- Testing
- TxAccess, Donor-Derived Cell-Free DNA (dd-cfDNA)
- Volunteers
- 450 people
- Sponsor
- Duke University
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
The purpose of this study is to find out the effects of using a system called CliniMACS to remove Tcells from blood stem cells. Removing T-cells may help stop a side effect called Graft-Versus-Host Disease (GVHD).
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Trial name
- NCT01119066
- Testing
- total body irradiation, Thiotepa, Cyclophosphamide
- Where
- United States
- Volunteers
- 422 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bone Marrow Transplantation, Blood Disease
Retention of Bone Marrow Donors in a National Registry
To identify factors that affected the National Marrow Donor Program's (NMDP) success in retention of bone marrow volunteers.
- Trial name
- NCT00005556
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Myeloid Leukemia
Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia
This pilot phase I trial studies the side effects of total bone marrow and lymphoid irradiation and how well it works with cyclophosphamide in treating patients with acute myeloid leukemia.
- Trial name
- NCT03467386
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- City of Hope Medical Center
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
Patients less than or equal to 21 years old with high-risk hematologic malignancies who would likely benefit from allogeneic hematopoietic cell transplantation (HCT).
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), NK-Cell Leukemia
- Trial name
- NCT03849651
- Testing
- Cyclophosphamide, Fludarabine, Thiotepa
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- St. Jude Children's Research Hospital
Hematologic Neoplasms
Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors
The purpose of this study is to determine if engraftment can be achieved safely in patients with high-risk hematologic malignancies who undergo non-myeloablative transplant with peripheral stem cells from Human Leukocyte Antigen…
- Trial name
- NCT01374841
- Testing
- Cyclophosphamide, Hematopoietic Stem Cell Transplantation,
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- European Institute of Oncology
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT03802695
- Testing
- OrcaGraft (Orca-Q)
- Where
- 12 sites in United States
- Volunteers
- 300 people
- Sponsor
- Orca Biosystems, Inc.
Leukemia, Myeloid, Chronic, AML
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia
In this study our hypothesis is that infusion of donor lymphocyte immune cells from the subject's bone marrow donor will activate the subject's immune system to attack their cancer.
- Conditions
- Leukemia, Myeloid, Chronic, AML, MDS, Leukemia, Lymphocytic, Acute
- Trial name
- NCT00167167
- Testing
- Donor Lymphocyte Infusion
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lung Transplant Recipient, Donor Specific Antibodies
DSA Intragraft in Lung Transplantation: Diagnostic and Prognostic Value in Antibody Mediated Rejection
The diagnosis of AMR in lung transplant recipients is difficult and often comes too late, because of lack of standardized definition.
- Conditions
- Lung Transplant Recipient, Donor Specific Antibodies, Antibody Mediated Rejection
- Trial name
- NCT03702257
- Testing
- bronchoscopy.
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Strasbourg, France
Lipid Metabolism Disorder
Multicomponent Intervention Study- Blood Donors With High Cholesterol
The purpose and objective of this study is to improve cholesterol treatment among blood donors with FH (Familial Hypercholesterolemia).
- Trial name
- DONATE-FH (NCT05693701)
- Testing
- Implementation Strategy Bundle, Usual care notification
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Texas Southwestern Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.